Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02205840 · ClinicalTrials.gov registry record · Phase 2

A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye.

A Phase 2 study of Dry Eye Syndromes, sponsored by Seikagaku Corporation.

Completed
Registry status
Phase 2
Development phase
240
Enrollment target
1
Study location

NCT02205840 is a Phase 2 study of Dry Eye Syndromes that has completed, run by Seikagaku Corporation. The registered enrollment target is 240 participants, below the 400-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02205840, a Phase 2 study of Dry Eye Syndromes, has completed, sponsored by Seikagaku Corporation.

COMPLETED
Registry status
Phase 2
Development phase
240 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the safety and effectiveness of SI-614 solution compared with placebo solution in treating patients with dry eye.

Conditions Studied

Interventions

  • DRUG Vehicle
  • DRUG SI-614

Study Locations (1)

Massachusetts

  • - Andover

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2014-07
Phase Phase 2

Sponsor

Seikagaku Corporation

12 total trials

What the Registry Record Tells You About NCT02205840

The ClinicalTrials.gov registry entry for NCT02205840 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 400-participant average among 17 other Dry Eye Syndromes trials with a reported enrollment target (40% lower). The listed sponsor is Seikagaku Corporation, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dry Eye Syndromes appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.

NCT02205840 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02205840 about?

NCT02205840 is a clinical study titled "A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye.". The purpose of this study is to assess the safety and effectiveness of SI-614 solution compared with placebo solution in treating patients with dry eye.

What is the current status of trial NCT02205840?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2014-07.

What conditions does trial NCT02205840 study?

This clinical trial studies the following conditions: Dry Eye Syndromes.

What interventions are being tested in trial NCT02205840?

The interventions under investigation include: Vehicle (DRUG), SI-614 (DRUG).

Who is sponsoring clinical trial NCT02205840?

This trial is sponsored by Seikagaku Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02205840 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dry Eye Syndromes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.